Biblio

Author Title Type [ Year

]

Filters: Author is Uchida, Naoyuki [Clear All Filters]

2024

Konuma T, Harada K, Shinohara A, Uchida N, Shingai N, Ito A, Ozawa Y, Tanaka M, Sawa M, Onizuka M, et al. Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japane. Am J Hematol. 2024.

Yamaguchi K, Yamamoto H, Izutsu K, Yuasa M, Kaji D, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Asano-Mori Y, et al. Fatal outcome of BK virus encephalitis in an allogeneic stem cell transplantation recipient. J Infect Chemother. 2024.

Jo T, Ueda T, Akahoshi Y, Kondo T, Uchida N, Tanaka M, Nakamae H, Doki N, Ota S, Sawa M, et al. First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia. Br J Haematol. 2024.

Yamamoto R, Hiramoto N, Fujimoto A, Yamazaki H, Mori T, Uchida N, Doki N, Kato J, Nishikubo M, Kako S, et al. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024.

Nakaya Y, Nakamae H, Nishikubo M, Kondo E, Fukuda T, Hiramoto N, Mori Y, Nagafuji K, Eto T, Onishi Y, et al. Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma. Bone Marrow Transplant. 2024.

Kurosawa S, Shimomura Y, Ishiyama K, Fuse K, Shimazu Y, Doki N, Uchida N, Tanaka M, Takahashi S, Sakurai M, et al. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study. Bone Marrow Transplant. 2024.

2023

Okada Y, Kimura F, Kurita N, Takahashi H, Shimazu Y, Mizuno S, Uchida N, Kataoka K, Hiramoto N, Ota S, et al. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma. Cytotherapy. 2023.

Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, et al. Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.

Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, et al. Author Correction: A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond). 2023;3(1):89.

Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida S-I, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, et al. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs. Haematologica. 2023.

Fuji S, Inoue Y, Makiyama J, Nakano N, Ito A, Kawakita T, Eto T, Suehiro Y, Itonaga H, Sawayama Y, et al. The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2023.

Okinaka K, Inoue Y, Uchida N, Toya T, Ogawa H, Ozawa Y, Eto T, Mori T, Sugita J, Kondo T, et al. Clinical characteristics and risk factors of pneumococcal diseases in recipients of allogeneic hematopoietic stem cell transplants in the late phase: A retrospective registry study. J Infect Chemother. 2023.

Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, et al. Comparison of allogeneic transplant outcomes between matched sibling donors and alternative donors in patients over 50 years of age with acute myeloid leukemia: 8/8 allele-matched unrelated donors and unrelated cord blood provide better leukemia-free surv. Transplant Cell Ther. 2023.

Onishi Y, Mori T, Yamazaki H, Hiramoto N, Zaimoku Y, Kanaya M, Matsue K, Onizuka M, Aotsuka N, Uchida N, et al. Comparison of haploidentical stem cell transplantation with post-transplant cyclophosphamide versus umbilical cord blood transplantation in adult patients with aplastic anemia. Transplant Cell Ther. 2023.

Koresawa-Shimizu R, Suzuki R, Uehara Y, Hiramoto N, Sawa M, Fukuda T, Kataoka K, Kanda Y, Oyake T, Kubota Y, et al. Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry. Bone Marrow Transplant. 2023.

Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, et al. A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond). 2023;3(1):67.

Tokunaga M, Nakano N, Fuji S, Wake A, Utsunomiya A, Ito A, Eto T, Kawakita T, Mori Y, Moriuchi Y, et al. Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study. Bone Marrow Transplant. 2023.

Wakamatsu M, Murata M, Kanda J, Fukushima K, Fukuda T, Najima Y, Katayama Y, Ozawa Y, Tanaka M, Kanda Y, et al. Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation. Int J Hematol. 2023.

Konuma T, Matsuda K, Shimomura Y, Tanoue S, Sugita J, Inamoto Y, Hirayama M, Ara T, Nakamae H, Ota S, et al. Effect of graft-versus-host disease on posttransplant outcomes following single cord blood transplantation in comparison to haploidentical transplantation with posttransplant cyclophosphamide for adult acute myeloid leukemia. Transplant Cell Ther. 2023.

Yamasaki S, Mizuno S, Iwasaki M, Seo S, Uchida N, Shigesaburo M, Nakano N, Ishiwata K, Uehara Y, Eto T, et al. Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics. Ann Hematol. 2023.

Hirabayashi S, Kondo T, Nishiwaki S, Mizuta S, Doki N, Fukuda T, Uchida N, Ozawa Y, Kanda Y, Imanaka R, et al. Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph ALL: A retrospective nationwide study. Am J Hematol. 2023.

Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, Nishida T, Kako S, Fujiwara S-I, Katayama Y, et al. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation a. Cytotherapy. 2023.

Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, et al. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci. 2023.

Takenaka K, Fuji S, Matsukawa T, Uchida N, Kobayashi T, Tanaka M, Ara T, Ikegame K, Ozawa Y, Kanda Y, et al. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection. Ann Hematol. 2023.

Kaida K, Ikegame K, Inoue T, Maruyama S, Ishii S, Uchida N, Doki N, Eto T, Fukuda T, Katayama Y, et al. Peritransplant glucocorticoid haploidentical stem cell transplantation is a promising strategy for AML patients with high leukemic burden: Comparison with transplants using other donor types. Transplant Cell Ther. 2023.

Pages